Drug Profile
Emixustat - Kubota Vision
Alternative Names: ACU-02; ACU-4429; ACU-4429 HCl; Emixustat HCl; Emixustat hydrochlorideLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Acucela
- Developer Kubota Vision; Otsuka Pharmaceutical
- Class Cyclohexanes; Eye disorder therapies; Phenyl ethers; Propanolamines; Small molecules
- Mechanism of Action Retinoid isomerohydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Stargardt disease
- Phase II Diabetic retinopathy
- Discontinued Dry age-related macular degeneration
Most Recent Events
- 23 Jun 2022 Kubota Vision completes the phase III SeaSTAR trial in Stargardt disease in US, Brazil, Canada, Denmark, France, Germany, Italy, the Netherlands, South Africa, Spain and the UK (PO) (NCT03772665) (EudraCT2018-003498-82)
- 09 Mar 2022 Emixustat is still in phase III trials for Stargardt disease (In adolescents, In adults, In the elderly) in United Kingdom, Brazil, Denmark, Canada, France, Germany, Italy, Netherlands, South Africa, Spain and USA (PO) (NCT03772665)
- 25 Nov 2020 Efficacy and adverse events data from a phase II trial in Stargardt disease released by Acucela